We planned long and hard for a great start of 2017. From January 9 to 13, the Novor team will be at the PepTalk conference hosted at Hilton San Diego Bayfront, San Diego, California. We are thrilled to have the opportunity to share our experiences and best practices we developed during our journey in session T5A: Characterization of Biotherapeutics (16) at 9:35am, Tuesday, January 10.
The presentation, Sequencing Antibody Proteins with Mass Spectrometry, will be delivered by our co-founder, Mingjie. Here is a quick outline of his talk.
- Concept, workflow and key components of the antibody protein sequencing technology
- Common pitfalls facing scientists when performing the sequencing work
- Best practices developed at Rapid Novor to ensure sequencing quality
If you are involved in the work of antibody discovery, generation, characterization, confirmation, engineering or simply are interested, I invite you to our talk and visit our booth #505 for discussions.
You can find a general description of our service at https://novor.cloud/antibody/.
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics